Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Protagonist Therapeutics Q3 2026 Results: Turns Profitable, Net Income $220M

Protagonist Therapeutics reported a significant increase in license and collaboration revenue to $544.3 million for the nine months ended September 30, 2026, resulting in a net income of $386.6 million compared to a net loss in the prior year. The company's cash position strengthened considerably, with total assets reaching $1.15 billion as of the end of the third quarter.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue274.44.7
Profit before tax226.6-39.3
Net income220.0-39.3
EPS (diluted, $ a share)$3.07$-0.62

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+5723.6%
Operating margin79.6%
Source

10-Q filed with the SEC, NASDAQ: PTGX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Protagonist Therapeutics, Inc: key numbers

Share price
$124.83Close, Nov 16
Market cap
$8.15B
Shares outstanding
65.27MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Protagonist Therapeutics, Inc

All →
4:22 PM ET 8-K
Financial Results

Protagonist Therapeutics Financial Results

Protagonist Therapeutics reported Q3 2026 financial results, highlighted by the FDA approval of MIMRYLO (rusfertide) for polycythemia vera, which triggered $275 million in payments from partner Takeda. The company ended the quarter with $834.6 million in cash and announced a $300 million share repurchase program.

Term
Q3 2026

“The third quarter was a defining period for Protagonist, with FDA approval of MIMRYLO, our second approval this year for a first-in-class peptide drug, and the continued strong commercial launch of ICOTYDE under our collaboration with Johnson & Johnson.”

Dinesh V. Patel, PhD, President and Chief Executive Officer

“The partnerships are fueling an accelerating revenue engine, which provides the flexibility to fund the next generation of wholly owned programs emerging from our platform, and to return meaningful capital to shareholders through a share repurchase program.”

Dinesh V. Patel, PhD, President and Chief Executive Officer
4:10 PM ET Form 4
Insider Selling

Protagonist Therapeutics CFO Asif Ali Sells $8.31M of Stock

Asif Ali, CFO, sold 58,629 shares of Protagonist Therapeutics, Inc at $141.77 to $141.78 a share (average $141.78) in 2 transactions, worth $8.31M in total on Sep 30, 2026. Shares held after the trade: 59,003 (-43.8%).

Value
$8.31M
Shares
58,629
Average price
$141.78
Role
CFO
Holding change
-43.8%
Trade date
Sep 30, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.